-Professeur Jean-Pierre GIES
Faculté de Pharmacie
Equipe de Signalisation cellulaire
UMR 7175-LC1
74, Route du Rhin, BP 24
67401 ILLKIRCH CEDEX
Tél. (33) 03 90 24 41 40
Bonjour,
Nous vous adressons l'annonce d'un Séminaire que nous organisons le Vendredi 13 juillet
prochain. Nous vous invitons à transmettre cette information à vos équipes et vous remercions
de bien vouloir nous informer du nom des participants afin d'organiser leur venue.
Restant à votre disposition pour tout complément d'information et dans l'attente de vous lire,
Meilleures salutations,
Martine Brandt
Transgene SA
11 rue de Molsheim
F - 67082 Strasbourg Cedex
Tel : +33 (0)3.88.27.91.73
Fax : +33 (0)3.88.27.91.41
brandt@transgene.fr
www.transgene.fr
SEMINAR ANNOUNCEMENT
Friday, July 13th
11.00 am - 12.30 am : Seminar Room C
2.00 pm - 4.30 pm : Round Table Room C
Philip M. Arlen, M.D.
Director, Clinical Research Group
Laboratory of Tumor Immunology and Biology
Center for Cancer Research, National Cancer Institute
Title: "Combinatorial therapies utilizing cancer
Vaccines"
Round Table open to all
Publications

Madan RA, Lieberman R, Gulley JL, Dahut W, Arlen PM. Significant
Prostate-Specific Antigen (PSA) Response to Low-Dose
Ketoconazole in a Patient With Non-Metastatic AndrogenIndependent Prostate Cancer (AIPC) and a Review of the Literature.
Am J Ther. 2007 May-Jun;14(3):310-3. PMID: 17515709 [PubMed in process]

Yokokawa J, Bera TK, Palena C, Cereda V, Remondo C, Gulley JL,
Arlen PM, Pastan I, Schlom J, Tsang KY. Identification of cytotoxic
T-lymphocyte epitope(s) and its agonist epitope(s) of a novel target
for vaccine therapy (PAGE4). Int J Cancer. 2007 Aug 1;121(3):595605. PMID: 17397028 [PubMed - in process]

Madan RA, Arlen PM, Gulley JL. PANVAC-VF: poxviral-based
vaccine therapy targeting CEA and MUC1 in carcinoma. Expert Opin
Biol Ther. 2007 Apr;7(4):543-54. Review. PMID: 17373905 [PubMed
- indexed for MEDLINE]

Wu SL, Jones E, Gulley JL, Arlen PM, Chen CC, Figg WD, Dahut WL.
Routine interval computed tomography to detect new soft-tissue
disease might be unnecessary in patients with androgenindependent prostate cancer and metastasis only to bone. BJU Int.
2007 Mar;99(3):525-8. Epub 2006 Nov 28. PMID: 17155971
[PubMed - indexed for MEDLINE]

Leonard GD, Dahut WL, Gulley JL, Arlen PM, Figg WD. Docetaxel
and thalidomide as a treatment option for androgen-independent,
nonmetastatic prostate cancer. Rev Urol. 2003;5 Suppl 3:S65-70.
PMID: 16985953 [PubMed - in process]

Arlen PM, Dahut WL, Gulley JL. Immunotherapy for prostate
cancer: what's the future? Hematol Oncol Clin North Am. 2006
Aug;20(4):965-83, xi. Review. PMID: 16861126 [PubMed - indexed
for MEDLINE]

Lattouf JB, Arlen PM, Pinto PA, Gulley JL. A phase I feasibility study
of an intraprostatic prostate-specific antigen-based vaccine in
patients with prostate cancer with local failure after radiation
therapy or clinical progression on androgen-deprivation therapy in
the absence of local definitive therapy. Clin Genitourin Cancer. 2006
Jun;5(1):89-92. No abstract available. PMID: 16859586 [PubMed indexed for MEDLINE]

Arlen PM, Pazdur M, Skarupa L, Rauckhorst M, Gulley JL. A
randomized phase II study of docetaxel alone or in combination with
PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with
metastatic breast cancer (NCI 05-C-0229). Clin Breast Cancer. 2006
Jun;7(2):176-9. No abstract available. PMID: 16800982 [PubMed indexed for MEDLINE]

Ahlers CM, Camphausen K, Citrin D, Arlen PM, Gulley JL. A pilot
trial of a carcinoembryonic antigen/ TRICOM-based vaccine and
radiation to liver metastases in patients with carcinoembryonic
antigen-positive solid tumors. Clin Colorectal Cancer. 2006
May;6(1):72-5. No abstract available. PMID: 16796796 [PubMed indexed for MEDLINE]

Tarassoff CP, Arlen PM, Gulley JL. Therapeutic vaccines for prostate
cancer. Oncologist. 2006 May;11(5):451-62. Review. PMID:
16720845 [PubMed - indexed for MEDLINE]

Madan RA, Gulley JL, Arlen PM. PSA-based vaccines for the
treatment of prostate cancer. Expert Rev Vaccines. 2006
Apr;5(2):199-209. Review. PMID: 16608420 [PubMed - indexed for
MEDLINE]

Arlen PM, Gulley JL. Docetaxel-based regimens, the standard of
care for metastatic androgen-insensitive prostate cancer. Future
Oncol. 2005 Feb;1(1):19-22. PMID: 16555972 [PubMed - indexed
for MEDLINE]

Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicali D,
Beetham P, Tsang KY, Grosenbach DW, Feldman J, Steinberg SM,
Jones E, Chen C, Marte J, Schlom J, Dahut W. A randomized phase
II study of concurrent docetaxel plus vaccine versus vaccine alone in
metastatic androgen-independent prostate cancer. Clin Cancer Res.
2006 Feb 15;12(4):1260-9. PMID: 16489082 [PubMed - indexed for
MEDLINE]

Garnett CT, Greiner JW, Tsang KY, Kudo-Saito C, Grosenbach DW,
Chakraborty M, Gulley JL, Arlen PM, Schlom J, Hodge JW. TRICOM
vector based cancer vaccines. Curr Pharm Des. 2006;12(3):351-61.
Review. PMID: 16454749 [PubMed - indexed for MEDLINE]

Madan RA, Arlen PM. Abiraterone. Cougar Biotechnology. IDrugs.
2006 Jan;9(1):49-55. PMID: 16374734 [PubMed - indexed for
MEDLINE]

Dahut WL, Lakhani NJ, Gulley JL, Arlen PM, Kohn EC, Kotz H,
McNally D,Parr A, Nguyen D, Yang SX, Steinberg SM, Venitz J,
Sparreboom A, Figg WD. Phase I clinical trial of oral 2methoxyestradiol, an antiangiogenic and apoptotic agent, in patients
with solid tumors. Cancer Biol Ther. 2006 Jan;5(1):22-7. Epub 2006
Jan 22. PMID: 16357512 [PubMed - indexed for MEDLINE]

Arlen PM, Kaufman HL, DiPaola RS. Pox viral vaccine approaches.
Semin Oncol. 2005 Dec;32(6):549-55. Review. PMID: 16338420
[PubMed - indexed for MEDLINE]

Hodge JW, Greiner JW, Tsang KY, Sabzevari H, Kudo-Saito C,
Grosenbach DW, Gulley JL, Arlen PM, Marshall JL, Panicali D,
Schlom J.
Costimulatory molecules as adjuvants for immunotherapy. Front
Biosci. 2006 Jan 1;11:788-803. Review. PMID: 16146771 [PubMed indexed for MEDLINE]

Posadas EM, Gulley J, Arlen PM, Trout A, Parnes HL, Wright J, Lee
MJ, Chung EJ, Trepel JB, Sparreboom A, Chen C, Jones E, Steinberg
SM, Daniels A,Figg WD, Dahut WL. A phase II study of perifosine in
androgen independent prostate cancer. Cancer Biol Ther. 2005
Oct;4(10):1133-7. Epub 2005 Oct 1. PMID: 16138006 [PubMed indexed for MEDLINE]

Arlen PM, Gulley JL, Todd N, Lieberman R, Steinberg SM, Morin S,
Bastian A, Marte J, Tsang KY, Beetham P, Grosenbach DW, Schlom
J, Dahut W. Antiandrogen, vaccine and combination therapy in
patients with nonmetastatic hormone refractory prostate cancer. J
Urol. 2005 Aug;174(2):539-46. PMID: 16006888 [PubMed - indexed
for MEDLINE]